Skip to main content
Top
Published in: Diabetologia 9/2011

Open Access 01-09-2011 | Article

Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet

Authors: P. M. Jamieson, M. E. Cleasby, Y. Kuperman, N. M. Morton, P. A. T. Kelly, D. G. Brownstein, K. J. Mustard, J. M. Vaughan, R. N. Carter, C. N. Hahn, D. G. Hardie, J. R. Seckl, A. Chen, W. W. Vale

Published in: Diabetologia | Issue 9/2011

Login to get access

Abstract

Aims/hypothesis

Urocortins are the endogenous ligands for the corticotropin-releasing factor receptor type 2 (CRFR2), which is implicated in regulating energy balance and/or glucose metabolism. We determined the effects of chronic CRFR2 activation on metabolism in vivo, by generating and phenotyping transgenic mice overproducing the specific CRFR2 ligand urocortin 3.

Methods

Body composition, glucose metabolism, insulin sensitivity, energy efficiency and expression of key metabolic genes were assessed in adult male urocortin 3 transgenic mice (Ucn3 + ) under control conditions and following an obesogenic high-fat diet (HFD) challenge.

Results

Ucn3 + mice had increased skeletal muscle mass with myocyte hypertrophy. Accelerated peripheral glucose disposal, increased respiratory exchange ratio and hypoglycaemia on fasting demonstrated increased carbohydrate metabolism. Insulin tolerance and indices of insulin-stimulated signalling were unchanged, indicating these effects were not mediated by increased insulin sensitivity. Expression of the transgene in Crfr2 (also known as Crhr2)-null mice negated key aspects of the Ucn3 + phenotype. Ucn3 + mice were protected from the HFD-induced hyperglycaemia and increased adiposity seen in control mice despite consuming more energy. Expression of uncoupling proteins 2 and 3 was higher in Ucn3 + muscle, suggesting increased catabolic processes. IGF-1 abundance was upregulated in Ucn3 + muscle, providing a potential paracrine mechanism in which urocortin 3 acts upon CRFR2 to link the altered metabolism and muscular hypertrophy observed.

Conclusions/interpretation

Urocortin 3 acting on CRFR2 in skeletal muscle of Ucn3 + mice results in a novel metabolically favourable phenotype, with lean body composition and protection against diet-induced obesity and hyperglycaemia. Urocortins and CRFR2 may be of interest as potential therapeutic targets for obesity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lovenberg TW, Liaw CW, Grigoriadis DE et al (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92:836–840PubMedCrossRef Lovenberg TW, Liaw CW, Grigoriadis DE et al (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92:836–840PubMedCrossRef
2.
go back to reference Vaughan JM, Donaldson C, Bittencourt J et al (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287–292PubMedCrossRef Vaughan JM, Donaldson C, Bittencourt J et al (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287–292PubMedCrossRef
3.
go back to reference Reyes TM, Lewis K, Perrin MH et al (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843–2848PubMedCrossRef Reyes TM, Lewis K, Perrin MH et al (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843–2848PubMedCrossRef
4.
go back to reference Lewis K, Li C, Perrin MH et al (2001) Identification of Urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570–7575PubMedCrossRef Lewis K, Li C, Perrin MH et al (2001) Identification of Urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570–7575PubMedCrossRef
5.
go back to reference Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7:605–611PubMedCrossRef Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7:605–611PubMedCrossRef
6.
go back to reference Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23–33PubMedCrossRef Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23–33PubMedCrossRef
7.
go back to reference Broberger C (2005) Brain regulation of food intake and appetite: molecules and networks. J Intern Med 258:301–327PubMedCrossRef Broberger C (2005) Brain regulation of food intake and appetite: molecules and networks. J Intern Med 258:301–327PubMedCrossRef
8.
go back to reference Black PH (2006) The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Med Hypotheses 67:879–891PubMedCrossRef Black PH (2006) The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Med Hypotheses 67:879–891PubMedCrossRef
9.
go back to reference Bale TL, Anderson KR, Roberts A, Lee K-F, Nagy TR, Vale WW (2003) Corticotropin-releasing factor receptor-2 deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 144:2580–2587PubMedCrossRef Bale TL, Anderson KR, Roberts A, Lee K-F, Nagy TR, Vale WW (2003) Corticotropin-releasing factor receptor-2 deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 144:2580–2587PubMedCrossRef
10.
go back to reference Carlin KM, Vale WW, Bale TL (2006) Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc Natl Acad Sci USA 103:3462–3467PubMedCrossRef Carlin KM, Vale WW, Bale TL (2006) Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc Natl Acad Sci USA 103:3462–3467PubMedCrossRef
11.
go back to reference Chen A, Brar B, Choi CS et al (2006) Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 103:16580–16585PubMedCrossRef Chen A, Brar B, Choi CS et al (2006) Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 103:16580–16585PubMedCrossRef
12.
go back to reference Li C, Chen P, Vaughan J et al (2003) Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology 144:3216–3224PubMedCrossRef Li C, Chen P, Vaughan J et al (2003) Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology 144:3216–3224PubMedCrossRef
13.
go back to reference Solinas G, Summermatter S, Mainieri D et al (2006) Corticotropin-releasing hormone directly stimulates thermogenesis in skeletal muscle possibly through substrate cycling between de novo lipogenesis and lipid oxidation. Endocrinology 147:31–38PubMedCrossRef Solinas G, Summermatter S, Mainieri D et al (2006) Corticotropin-releasing hormone directly stimulates thermogenesis in skeletal muscle possibly through substrate cycling between de novo lipogenesis and lipid oxidation. Endocrinology 147:31–38PubMedCrossRef
14.
go back to reference Li C, Chen P, Vaughan J, Lee KF, Vale W (2007) Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA 104:4206–4211PubMedCrossRef Li C, Chen P, Vaughan J, Lee KF, Vale W (2007) Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA 104:4206–4211PubMedCrossRef
15.
go back to reference Bale TL, Contarino A, Smith GW et al (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Gen 24:410–414CrossRef Bale TL, Contarino A, Smith GW et al (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Gen 24:410–414CrossRef
16.
go back to reference Nagy TR, Clair AL (2000) Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 8:392–398PubMedCrossRef Nagy TR, Clair AL (2000) Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 8:392–398PubMedCrossRef
17.
go back to reference Brooke MH, Kaiser KK (1970) Muscle fiber types: how many and what kind? Arch Neurol 23:369–379PubMed Brooke MH, Kaiser KK (1970) Muscle fiber types: how many and what kind? Arch Neurol 23:369–379PubMed
18.
go back to reference Sokoloff L, Reivich M, Kennedy C et al (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916PubMedCrossRef Sokoloff L, Reivich M, Kennedy C et al (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916PubMedCrossRef
19.
go back to reference Cleasby ME, Davey JR, Reinten TA et al (2005) Acute bidirectional manipulation of muscle glucose uptake by in vivo electrotransfer of constructs targeting glucose transporter genes. Diabetes 54:2702–2711PubMedCrossRef Cleasby ME, Davey JR, Reinten TA et al (2005) Acute bidirectional manipulation of muscle glucose uptake by in vivo electrotransfer of constructs targeting glucose transporter genes. Diabetes 54:2702–2711PubMedCrossRef
20.
go back to reference Chan TM, Exton JH (1976) A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96–105PubMedCrossRef Chan TM, Exton JH (1976) A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96–105PubMedCrossRef
21.
go back to reference Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067PubMedCrossRef Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067PubMedCrossRef
22.
go back to reference Jamieson PM, Nyirenda MJ, Walker BR, Chapman KE, Seckl JR (1999) Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11beta-hydroxysteroid dehydrogenase type 1. J Endocrinol 160:103–109PubMedCrossRef Jamieson PM, Nyirenda MJ, Walker BR, Chapman KE, Seckl JR (1999) Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11beta-hydroxysteroid dehydrogenase type 1. J Endocrinol 160:103–109PubMedCrossRef
23.
go back to reference Jamieson PM, Chapman KE, Edwards CR, Seckl JR (1995) 11 beta-Hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136:4754–4761PubMedCrossRef Jamieson PM, Chapman KE, Edwards CR, Seckl JR (1995) 11 beta-Hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136:4754–4761PubMedCrossRef
24.
go back to reference Richter EA, Ruderman NB (2009) AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 418:261–275PubMedCrossRef Richter EA, Ruderman NB (2009) AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 418:261–275PubMedCrossRef
25.
go back to reference Livesey G, Elia M (1988) Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels. Am J Clin Nutr 47:608–628PubMed Livesey G, Elia M (1988) Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels. Am J Clin Nutr 47:608–628PubMed
26.
go back to reference Bezaire V, Seifert EL, Harper ME (2007) Uncoupling protein-3: clues in an ongoing mitochondrial mystery. FASEB J 21:312–324PubMedCrossRef Bezaire V, Seifert EL, Harper ME (2007) Uncoupling protein-3: clues in an ongoing mitochondrial mystery. FASEB J 21:312–324PubMedCrossRef
27.
go back to reference Brand MD, Esteves TC (2005) Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2:85–93PubMedCrossRef Brand MD, Esteves TC (2005) Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2:85–93PubMedCrossRef
28.
go back to reference Bezaire V, Spriet LL, Campbell S et al (2005) Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation. FASEB J 19:977–979PubMed Bezaire V, Spriet LL, Campbell S et al (2005) Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation. FASEB J 19:977–979PubMed
29.
go back to reference Li B, Nolte LA, Ju JS et al (2000) Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat Med 6:1115–1120PubMedCrossRef Li B, Nolte LA, Ju JS et al (2000) Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat Med 6:1115–1120PubMedCrossRef
30.
go back to reference Tsuboyama-Kasaoka N, Tsunoda N, Maruyama K et al (1999) Overexpression of GLUT4 in mice causes up-regulation of UCP3 mRNA in skeletal muscle. Biochem Biophys Res Commun 258:187–193PubMedCrossRef Tsuboyama-Kasaoka N, Tsunoda N, Maruyama K et al (1999) Overexpression of GLUT4 in mice causes up-regulation of UCP3 mRNA in skeletal muscle. Biochem Biophys Res Commun 258:187–193PubMedCrossRef
31.
go back to reference Dilger AC, Spurlock ME, Grant AL, Gerrard DE (2010) Myostatin null mice respond differently to dietary-induced and genetic obesity. Anim Sci J 81:586–593PubMedCrossRef Dilger AC, Spurlock ME, Grant AL, Gerrard DE (2010) Myostatin null mice respond differently to dietary-induced and genetic obesity. Anim Sci J 81:586–593PubMedCrossRef
32.
go back to reference Schmitz F, Hartmann H, Stumpel F, Creutzfeldt W (1991) In vivo metabolic action of insulin-like growth factor I in adult rats. Diabetologia 34:144–149PubMedCrossRef Schmitz F, Hartmann H, Stumpel F, Creutzfeldt W (1991) In vivo metabolic action of insulin-like growth factor I in adult rats. Diabetologia 34:144–149PubMedCrossRef
33.
go back to reference Dimitriadis G, Parry-Billings M, Bevan S et al (1992) Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochem J 285(Pt 1):269–274PubMed Dimitriadis G, Parry-Billings M, Bevan S et al (1992) Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochem J 285(Pt 1):269–274PubMed
34.
go back to reference Di Cola G, Cool MH, Accili D (1997) Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99:2538–2544PubMedCrossRef Di Cola G, Cool MH, Accili D (1997) Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99:2538–2544PubMedCrossRef
35.
go back to reference Semsarian C, Wu MJ, Ju YK et al (1999) Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway. Nature 400:576–581PubMedCrossRef Semsarian C, Wu MJ, Ju YK et al (1999) Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway. Nature 400:576–581PubMedCrossRef
36.
go back to reference LeBrasseur NK, Walsh K, Arany Z (2011) Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol Endocrinol Metab 300:E3–E10PubMedCrossRef LeBrasseur NK, Walsh K, Arany Z (2011) Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol Endocrinol Metab 300:E3–E10PubMedCrossRef
37.
go back to reference Morrow LA, O’Brien MB, Moller DE, Flier JS, Moses AC (1994) Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205–210PubMedCrossRef Morrow LA, O’Brien MB, Moller DE, Flier JS, Moses AC (1994) Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205–210PubMedCrossRef
38.
go back to reference Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316–328PubMedCrossRef Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316–328PubMedCrossRef
39.
go back to reference Holmberg BJ, Morrison CD, Keisler DH (2001) Endocrine responses of ovariectomized ewes to i.c.v. infusion of urocortin. J Endocrinol 171:517–524PubMedCrossRef Holmberg BJ, Morrison CD, Keisler DH (2001) Endocrine responses of ovariectomized ewes to i.c.v. infusion of urocortin. J Endocrinol 171:517–524PubMedCrossRef
40.
go back to reference Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD (1989) Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124:40–48PubMedCrossRef Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD (1989) Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124:40–48PubMedCrossRef
41.
go back to reference Mathews LS, Hammer RE, Behringer RR et al (1988) Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123:2827–2833PubMedCrossRef Mathews LS, Hammer RE, Behringer RR et al (1988) Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123:2827–2833PubMedCrossRef
42.
go back to reference Coleman ME, DeMayo F, Yin KC et al (1995) Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 270:12109–12116PubMedCrossRef Coleman ME, DeMayo F, Yin KC et al (1995) Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 270:12109–12116PubMedCrossRef
43.
go back to reference Musaro A, McCullagh K, Paul A et al (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195–200PubMedCrossRef Musaro A, McCullagh K, Paul A et al (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195–200PubMedCrossRef
44.
go back to reference Argiles JM, Figueras M, Ametller E et al (2008) Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 37:190–195PubMedCrossRef Argiles JM, Figueras M, Ametller E et al (2008) Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 37:190–195PubMedCrossRef
45.
go back to reference Hinkle RT, Donnelly E, Cody DB, Bauer MB, Sheldon RJ, Isfort RJ (2004) Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. J Muscle Res Cell Motil 25:539–547PubMedCrossRef Hinkle RT, Donnelly E, Cody DB, Bauer MB, Sheldon RJ, Isfort RJ (2004) Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. J Muscle Res Cell Motil 25:539–547PubMedCrossRef
46.
go back to reference Hinkle RT, Donnelly E, Cody DB et al (2003) Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol Endocrinol Metab 285:E889–E898PubMed Hinkle RT, Donnelly E, Cody DB et al (2003) Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol Endocrinol Metab 285:E889–E898PubMed
47.
go back to reference Shavlakadze T, Winn N, Rosenthal N, Grounds MD (2005) Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 15:4–18PubMedCrossRef Shavlakadze T, Winn N, Rosenthal N, Grounds MD (2005) Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 15:4–18PubMedCrossRef
48.
go back to reference Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91–100PubMedCrossRef Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91–100PubMedCrossRef
49.
go back to reference Pennisi P, Gavrilova O, Setser-Portas J et al (2006) Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619–2630PubMedCrossRef Pennisi P, Gavrilova O, Setser-Portas J et al (2006) Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619–2630PubMedCrossRef
50.
go back to reference Wang J, Xu Y, Zhu H, Zhang R, Zhang G, Li S (2008) Urocortin’s inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26:359–368PubMedCrossRef Wang J, Xu Y, Zhu H, Zhang R, Zhang G, Li S (2008) Urocortin’s inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26:359–368PubMedCrossRef
Metadata
Title
Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet
Authors
P. M. Jamieson
M. E. Cleasby
Y. Kuperman
N. M. Morton
P. A. T. Kelly
D. G. Brownstein
K. J. Mustard
J. M. Vaughan
R. N. Carter
C. N. Hahn
D. G. Hardie
J. R. Seckl
A. Chen
W. W. Vale
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2205-6

Other articles of this Issue 9/2011

Diabetologia 9/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.